Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas

BACKGROUND: Changes in glycosylation of the constant domain (Fc) of monoclonal antibodies (mAbs) enhance antibody-dependent cell-mediated cytotoxicity independently of downstream effects following receptor blockade by the antibody, thus extending their indication. We investigated the safety, pharmac...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:ESMO Open
Asıl Yazarlar: Fiedler, Walter, Cresta, Sara, Schulze-Bergkamen, Henning, De Dosso, Sara, Weidmann, Jens, Tessari, Anna, Baumeister, Hans, Danielczyk, Antje, Dietrich, Bruno, Goletz, Steffen, Zurlo, Alfredo, Salzberg, Marc, Sessa, Cristiana, Gianni, Luca
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2018
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5812399/
https://ncbi.nlm.nih.gov/pubmed/29464112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2017-000303
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller